Targeting DNA damage response pathways in cancer
FJ Groelly, M Fawkes, RA Dagg, AN Blackford… - Nature Reviews …, 2023 - nature.com
Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …
ATR/CHK1 inhibitors and cancer therapy
Z Qiu, NL Oleinick, J Zhang - Radiotherapy and Oncology, 2018 - Elsevier
The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have
thus far been disappointing owing to a lack of robust stratification methods. Whole-genome …
thus far been disappointing owing to a lack of robust stratification methods. Whole-genome …
Targeting the checkpoint to kill cancer cells
J Benada, L Macurek - Biomolecules, 2015 - mdpi.com
Cancer treatments such as radiotherapy and most of the chemotherapies act by damaging
DNA of cancer cells. Upon DNA damage, cells stop proliferation at cell cycle checkpoints …
DNA of cancer cells. Upon DNA damage, cells stop proliferation at cell cycle checkpoints …
Trial watch: targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
G Manic, F Obrist, A Sistigu, I Vitale - Molecular & cellular oncology, 2015 - Taylor & Francis
The ataxia telangiectasia mutated serine/threonine kinase (ATM)/checkpoint kinase 2
(CHEK2, best known as CHK2) and the ATM and Rad3-related serine/threonine kinase …
(CHEK2, best known as CHK2) and the ATM and Rad3-related serine/threonine kinase …
Cancer-specific synthetic lethality between ATR and CHK1 kinase activities
K Sanjiv, A Hagenkort, JM Calderón-Montaño… - Cell reports, 2016 - cell.com
ATR and CHK1 maintain cancer cell survival under replication stress and inhibitors of both
kinases are currently undergoing clinical trials. As ATR activity is increased after CHK1 …
kinases are currently undergoing clinical trials. As ATR activity is increased after CHK1 …
Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma
N Barnaba, JR LaRocque - Cell Cycle, 2021 - Taylor & Francis
Disruption of cell cycle checkpoints has been well established as a hallmark of cancer. In
particular, the G1-S transition mediated by the cyclin D-cyclin-dependent kinase 4/6 …
particular, the G1-S transition mediated by the cyclin D-cyclin-dependent kinase 4/6 …
[HTML][HTML] Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants
Abstract Checkpoint kinase 1 (CHK1) is an essential kinase with a critical function in cell
cycle arrest. Several potent inhibitors targeting CHK1 have been published, but most of them …
cycle arrest. Several potent inhibitors targeting CHK1 have been published, but most of them …
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
S McNeely, R Beckmann, AKB Lin - Pharmacology & therapeutics, 2014 - Elsevier
CHEK1 encodes the serine/threonine kinase CHK1, a central component of the DNA
damage response. CHK1 regulates cell cycle checkpoints following genotoxic stress to …
damage response. CHK1 regulates cell cycle checkpoints following genotoxic stress to …
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
C King, H Diaz, D Barnard, D Barda, D Clawson… - Investigational new …, 2014 - Springer
Interference with DNA damage checkpoints has been demonstrated preclinically to be a
highly effective means of increasing the cytotoxicity of a number of DNA-damaging cancer …
highly effective means of increasing the cytotoxicity of a number of DNA-damaging cancer …